臭化ジスチグミンによる眼筋型筋無力症の治験例および基礎的実験

The Cases of Treatment in Myasthenia Gravis and Experimental Study with Distigmin Bromide

I．緒言

　Mary Walkerが，1935年，さらにEvertsがphy—sostigminを使用してから，本症の薬物治療が開始され，以来DFP, OMPA, TEPP, Tensilon, Mestinon etc種々のanticholinestelase剤が開発され，本症の薬物治療面に利用されてぎた。しかし，これらの一群の薬物には一長一短があり，その増量は副作用の発現となり，治療薬としてけつして良好なものとはいえない。かくして効果が低量にて，かつ安定持続し，副作用の発現が少ない薬物の出現が待たれる。

　今回，オーストリー窒素化学工業株式会社にて合成された臭化ジスチグミン（ウブレチド）を入手したので，本剤の治療効果ならびに基礎的実験について検討した。

A new anticholinestelase drug, Distigmin bromide, was used to myasthenia gravis and it's experimental effect was studied.

It's clinical effect was as follows.

(1) Strength of muscles of eye lids, limbs and body were increased effectively.

(2) Extraocular muscles were less reactive to distigmin bromide than the levator and skeletal muscles.

(3) The effctive dose was less than that of another anticholinestelase-drugs and the maintenance of clinical effect was more durable.

(4) Its side-effects were minimum in the pro-longed treatment.

Experimental examination with frog lectus and rat-brain tissue were as follows.